Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4251-4260

  Urano, Emiko ^a,b   Kuramochi, Noriko ^a   Ichikawa, Reiko ^b   Murayama, Somay Yamagata ^a   Miyauchi, Kosuke ^b   Tomoda, Hiroshi ^a   Takebe, Yutaka ^b   Nermut, Milan ^c   Komano, Jun ^b   Morikawa, Yuko ^a  

^a KITASATO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (BENZOTHIAZOL 2 YLMETHYLTHIO) 4 METHYLPYRIMIDINE; CAPSID PROTEIN; GAG PROTEIN; LUCIFERASE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MURINE LEUKEMIA VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; TWO HYBRID SYSTEM; VIRUS CAPSID; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; YEAST;

ANTI-HIV AGENTS; BENZOTHIAZOLES; CELL LINE; GENE PRODUCTS, GAG; HIV-1; HUMANS; MICROSCOPY, CONFOCAL; PYRIMIDINES; TWO-HYBRID SYSTEM TECHNIQUES; VIRUS REPLICATION;

EID: 80051813979     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00299-11     Document Type: Article

References (38)

1. Adamson, C S, et al. 2006. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J. Virol. 80:10957-10971. (Pubitemid 44706537)
2. Adamson, C S, K. Waki, S D Ablan, K. Salzwedel, and E O Freed. 2009. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J. Virol. 83:4884-4894.
3. Aiken, C. 2009. Cell-free assays for HIV-1 uncoating. Methods Mol. Biol. 485:41-53.
4. Aronheim, A., et al. 1994. Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway. Cell 78:949-961. (Pubitemid 24292324)
5. Bartonova, V., et al. 2008. Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J. Biol. Chem. 283:32024-32033.
6. Blair, W S, et al. 2005. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antiviral Res. 65:107-116. (Pubitemid 40222287)
7. Blair, W S, et al. 2009. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob. Agents Chemother. 53:5080-5087.
8. Botstein, D. 1997. Yeast as a model organism. Science 277:1259-1260. (Pubitemid 27449069)
9. Braaten, D., E K Franke, and J. Luban. 1996. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J. Virol. 70:3551-3560. (Pubitemid 26157335)
10. Broder, S. 2010. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 85:1-18.
11. Bukovsky, A A, A. Weimann, M A Accola, and H G Gottlinger. 1997. Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc. Natl. Acad. Sci. U. S. A. 94:10943-10948. (Pubitemid 27430840)
12. Butler, S L, M S T Hansen, and F D Bushman. 2001. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7:631-634. (Pubitemid 32448333)
13. Craven, R C, and L J Parent. 1996. Dynamic interactions of the Gag polyprotein. Curr. Top. Microbiol. Immunol. 214:65-94. (Pubitemid 27390712)
14. Forshey, B M, U. Von Schwedler, W I Sundquist, and C. Aiken. 2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76:5667-5677.
15. Franke, E K, H E Yuan, and J. Luban. 1994. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359-362. (Pubitemid 24363437)
16. Gamble, T R, et al. 1996. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87:1285-1294. (Pubitemid 27010111)
17. Ganser, B K, S. Li, V Y Klishko, J T Finch, and W I Sundquist. 1999. Assembly and analysis of conical models for the HIV-1 core. Science 283:80-83. (Pubitemid 29044851)
18. Ganser-Pornillos, B K, A. Cheng, and M. Yeager. 2007. Structure of full-length HIV-1 CA: A model for the mature capsid lattice. Cell 131:70-79. (Pubitemid 47498532)
19. INKb in relapsed childhood acute lymphoblastic leukemia. Blood 99:4629-4631.
20. Kelly, B N, et al. 2007. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J. Mol. Biol. 373:355-366. (Pubitemid 47445574)
21. Li, F., et al. 2003. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. U. S. A. 100:13555-13560. (Pubitemid 37444780)
22. Morikawa, Y. 2003. HIV capsid assembly. Curr. HIV Res. 1:1-14.
23. Pauwels, R., et al. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474. (Pubitemid 120028562)
24. Pornillos, O., et al. 2009. X-ray structures of the hexameric building block of the HIV capsid. Cell 137:1282-1292.
25. Roberts, N A, et al. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
26. Sakuragi, S., T. Goto, K. Sano, and Y. Morikawa. 2002. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 99:7956-7961. (Pubitemid 34650987)
27. Shi, J., J. Zhou, V B Shah, C. Aiken, and K. Whitby. 2011. Small molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85:542-549.
28. Shimizu, S., et al. 2007. Inhibiting lentiviral replication by HEXIM1, a cellular negative regulator of the CDK9/cyclin T complex. AIDS 21:575-582.
29. Sticht, J., et al. 2005. A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 12:671-677. (Pubitemid 43086272)
30. Stremlau, M., et al. 2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 103:5514-5519.
31. Suzuki, S., et al. 2010. Peptide HIV-1 integrase inhibitors from HIV-1 gene products. J. Med. Chem. 53:5356-5360.
32. Tang, C., et al. 2003. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 327:1013-1020. (Pubitemid 36363708)
33. Ternois, F., J. Sticht, S. Duquerroy, H G Krausslich, and F A Rey. 2005. The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor. Nat. Struct. Mol. Biol. 12:678-682. (Pubitemid 43086273)
34. Towers, G J, et al. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9:1138-1143. (Pubitemid 37173697)
35. Urano, E., et al. 2008. Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production. J. Gen. Virol. 89:3144-3149.
36. Von Schwedler, U K, et al. 1998. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J. 17:1555-1568. (Pubitemid 28119109)
37. Westby, M., G R Nakayama, S L Butler, and W S Blair. 2005. Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antiviral Res. 67:121-140. (Pubitemid 41254196)
38. Zhang, H., et al. 2008. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J. Mol. Biol. 378:565-580.